The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective

To cite this article: Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010; 65: 1141–1148.

[1]  Sylvia E. Rosas,et al.  MORBIDITY AND MORTALITY , 2010 .

[2]  M. Drummond,et al.  Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  Taichi Omachi,et al.  Risk of Mortality Associated with Asthma Exacerbation. , 2009, ATS 2009.

[4]  S. Sullivan,et al.  Health economics of asthma: assessing the value of asthma interventions , 2008, Allergy.

[5]  S. Sullivan,et al.  An evaluation of the cost‐effectiveness of omalizumab for the treatment of severe allergic asthma , 2008, Allergy.

[6]  S. Sullivan,et al.  Revisiting the cost‐effectiveness of omalizumab , 2007, Allergy.

[7]  K. Kuntz,et al.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. , 2007, The Journal of allergy and clinical immunology.

[8]  J. Bousquet,et al.  Cost‐effectiveness of omalizumab in patients with severe persistent allergic asthma , 2007, Allergy.

[9]  John B. Watkins,et al.  Managing biotechnology in a network-model health plan: a U.S. private payer perspective. , 2006, Health affairs.

[10]  T. Sandström,et al.  The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients:adaptation of INNOVATE to Sweden , 2006, Current medical research and opinion.

[11]  S. Peters,et al.  Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. , 2006, Respiratory medicine.

[12]  J. Bousquet,et al.  The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma , 2005, Allergy.

[13]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[14]  S. Walker,et al.  Anti-IgE for chronic asthma in adults and children. , 2006, The Cochrane database of systematic reviews.

[15]  J. C. Carranza Rosenzweig,et al.  The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. , 2004, Respiratory medicine.

[16]  Y. Oba,et al.  Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. , 2004, The Journal of allergy and clinical immunology.

[17]  E. Chilvers,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma , 2004, Allergy.

[18]  R. Pauwels,et al.  Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. , 2003, The Journal of allergy and clinical immunology.

[19]  J. Brazier,et al.  Deriving preference-based single indices from non-preference based condition-specific instruments: converting AQLQ into EQ5D indices , 2002 .

[20]  Barrett T. Kitch,et al.  Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. , 2001, The Journal of allergy and clinical immunology.

[21]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[22]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[23]  R. Patterson,et al.  Idiopathic anaphylaxis: long‐term follow‐up, cost, and outlook , 1996, Allergy.

[24]  G. Guyatt,et al.  Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. , 1992, Thorax.

[25]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[26]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[27]  R. Elenbaas,et al.  Failure of peak expiratory flow rate to predict hospital admission in acute asthma. , 1982, Annals of emergency medicine.